Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
An orally delivered GLP-1 analog coformulated with the absorption enhancer SNAC achieves transcellular-directed absorption in the stomach.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Yet, its adoption is restricted by a complicated dosing protocol that necessitates administration while fasting with water, as well as the avoidance of food or medications for a minimum of 30 min afterward. Such requirements reduce convenience and compromise adherence in routine practice [11, 16].”
From Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis (2025) · cites this paper as [16]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Pharmacologically, long-acting GLP-1 receptor agonists (GLP-1RAs) exhibit glucoregulatory functions via a triumvirate of mechanisms, namely, stimulation of insulin release in a glucose-dependent manner, suppression of glucagon activity during hyperglycemia, and a minor delay of gastric emptying resulting in slower glu…”
BackgroundDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 1×
“In line with this, recent advancements in fatty acid acylation– based protraction technology have provided the possibility of achieving extended plasma half-lives (t1⁄2) without increasing molecular size, leading to the discovery of semaglutide, a GLP-1 analog with a t1⁄2 of ~1 week in humans (8).”
BackgroundSelf-citationThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“In addition, GLP-1 promotes satiety and reduces energy intake by virtue of its neurotransmitter role in brainstem-hypothalamus pathways signaling satiety (3, 4), and some long-acting GLP-1RAs including semaglutide have shown cardiovascular risk reduction (5, 6).”
BackgroundSelf-citationIncretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Self-citationpH stability and activity curves of pepsin with special reference to their clinical importance.
Piper, D. W., & Fenton, B. H. (1965) · Gut · doi:10.1136/gut.6.5.506 · Cited by 385
Intestinal permeation enhancers for oral peptide delivery
Maher, S., Mrsny, R. J., & Brayden, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.005 · Cited by 381
Cited by
Items 301–400 of 599
Jiang, Y., Mi, L., Xu, X., Hii, A. R. K., Wu, Z., & Qi, X. (2024) · Biomaterials Science · doi:10.1039/d3bm01715j · Cited by 11
Discovery of Selenium-Containing Derivatives as Potent and Orally Bioavailable GLP-1R Agonists
Chen, X., Xu, S., Yang, S. C., Yu, Z.-Z., Chen, Y., Wu, H., Bao, Q., You, Q., Guo, X., & Jiang, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02616 · Cited by 11
Kitsunai, H., Shinozaki, Y., Furusawa, S., Kitao, N., Ito, M., Kurihara, H., Oba‐Yamamoto, C., Takeuchi, J., Nakamura, A., Takiyama, Y., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18010129 · Cited by 12
The expanding role of semaglutide: beyond glycemic control
Zarei, M., Sabetkasaei, M., Mozafari, M., & Zaeri, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01663-z · Cited by 11
Yoshida, T., & Kojima, H. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00482 · Cited by 11
Recent Advances in Oral and Transdermal Protein Delivery Systems
Yang, Y., Zhou, R., Wang, Y., Zhang, Y., Yu, J., & Gu, Z. (2022) · Angewandte Chemie · doi:10.1002/ange.202214795 · Cited by 11
The Effects of Dose Volume and Excipient Dose on Luminal Concentration and Oral Drug Absorption
Aungst, B. J. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00490-9 · Cited by 11
Evans, M., Morgan, A. R., Bain, S. C., Davies, S., Hicks, D., Brown, P., Yousef, Z., Dashora, U., Viljoen, A., Beba, H., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-021-01201-z · Cited by 10
Lee, H. Y., Ko, S.-H., Park, S., Kim, K., Kim, S.-Y., Cho, I.-J., Cho, E. J., Kim, H. C., Park, J.-H., Ryu, S. K., et al. (2024) · Clinical Hypertension · doi:10.1186/s40885-024-00279-4 · Cited by 10
“Oral semaglutide is combined with sodium N-[8-(2-hydroxybenzoyl) amino]- caprylate (SNAC), which allows entry of semaglutide in the circulation with a bioavailability of around 1% by functioning as an absorption enhancer [42].”
BackgroundTyagi, P., Patel, C., Gibson, K., MacDougall, F., Pechenov, S., Will, S., Revell, J. D., Huang, Y., Rosenbaum, A. I., Balic, K., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102436 · Cited by 10
Advances in Drug Treatments for Companion Animal Obesity
Zomer, H. D., & Cooke, P. S. (2024) · Biology · doi:10.3390/biology13050335 · Cited by 10
Lee, K.-J., Yang, S.-B., Lee, J.-H., Seo, B., Won, H., & Park, J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17040480 · Cited by 11
Recent advances and trends in oral absorption enhancements of GLP-1 receptor agonist formulations
Kim, D.-H., & Kim, J.-E. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00762-6 · Cited by 10
Khalid, N.-U.-A., Rivera‐Delgado, E., & von Erlach, T. C. (2026) · Frontiers in Drug Delivery · doi:10.3389/fddev.2026.1809842 · Cited by 10
Tran, H., Patel, P. J., Aburub, A., Sperry, A. E., Estwick, S. A., ElSayed, M. E. H., & Datta‐Mannan, A. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03372-1 · Cited by 10
Current Status of Therapeutic Peptides for the Management of Diabetes Mellitus
Prajapati, A., Rana, D., Rangra, S., Jindal, A. B., & Benival, D. M. (2024) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10590-1 · Cited by 10
Optimized suction patch design for enhanced transbuccal macromolecular drug delivery
Cerrejon, D. K., Krupke, H., Gao, D., Paunović, N., Sachs, D., & Leroux, J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.014 · Cited by 10
Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review
Sofogianni, A., & Τζιόμαλος, Κ. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01478-9 · Cited by 10
Interaction between Permeation Enhancers and Lipid Bilayers
Kang, C., Bernaldez, M., Stamatis, S. D., Rose, J. P., & Sun, R. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c06448 · Cited by 10
Lu, Y., Wang, C., Jiang, B., Sun, C. C., & Hoag, S. W. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120737 · Cited by 10
Pandey, R. K., Jan, M., Mohammad, A., Jawaid, K. A., Naveed, M., Abid, M. A., Amir, A. B., Ahmed, S., Safiullah, M., Bhatti, M. I., et al. (2025) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.70134 · Cited by 9
Impact of Permeation Enhancers on the Release of Insulin from Tablets in Biorelevant Media
Fagan, A., Bateman, L. M., Crean, A. M., O’Shea, J. P., & Taylor, L. S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00249 · Cited by 9
Zeng, H., Li, Y., Deng, X., Xiao, P., Liu, B., Zhang, Y. X., Yin, T., He, H., Gou, J., & Tang, X. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2524005 · Cited by 9
Overgaard, R. V., Birkhan, O. A., Rathor, N., Sparsø, T., Strathe, A., Wharton, S., & Rubino, D. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70769 · Cited by 9
The Synthesis of SNAC Phenolate Salts and the Effect on Oral Bioavailability of Semaglutide
Shapira‐Furman, T., Bar-Hai, A., Hoffman, A., & Domb, A. J. (2024) · Molecules · doi:10.3390/molecules29163909 · Cited by 9
Miao, L., Lou, J., Xu, S., Zhang, J., Zhong, Y., Wang, G., Li, Y., Lei, S., Shao, S., Wang, J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00231 · Cited by 9
Ghodge1, S. V., Biswas2, K., & Golosov3, A. A. (2022) · ACS symposium series · doi:10.1021/bk-2022-1417 · Cited by 9
Sun, L., Han, J. D. J., Chen, X., Han, Y., Wu, L., & Xia, E. (2019) · RSC Advances · doi:10.1039/c9ra00833k · Cited by 9
A biodegradable suction patch for sustainable transbuccal peptide delivery
Krupke, H., Zoratto, N., Rabut, L., Gao, D., Paunović, N., Cerrejon, D. K., Dehapiot, B., & Leroux, J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113947 · Cited by 8
Niazi, S. K. (2026) · Frontiers in Drug Delivery · doi:10.3389/fddev.2026.1776167 · Cited by 8
Management of Overweight and Obesity in Patients With Inflammatory Bowel Disease.
Shneyderman, M., Freid, H., Köhler, D., Peraza, J., Haskey, N., Abbott, E., Kornbluth, A. A., Raman, M., & Gold, S. L. (2024) · PubMed Central · Cited by 8
Microrheology of Ionic Liquid Doped Mucus for an Efficient Delivery of Protein‐Based Oral Drugs
Kakati, N., Paul, N., Dubey, S., Mahanta, J., Lakshmi, A. R., Banerjee, T., & Bandyopadhyay, D. (2025) · Small · doi:10.1002/smll.202500403 · Cited by 8
Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist
Powell, J., Piszczatoski, C., & Taylor, J. R. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.07.017 · Cited by 8
Hamza, A., & Șaramet, G. (2020) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2020.383 · Cited by 8
Feng, Z., Liu, Y., Kuang, Y., Yang, S., Li, J., Ye, L., Huang, J., Pei, Q., Huang, Y., & Yang, G. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s339305 · Cited by 8
Joshi, S., Rajput, R., Chowdhury, S., Singh, A. K., Bantwal, G., Das, A. K., Unnikrishnan, A., Saboo, B., Kesavadev, J., Ghosal, S., et al. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102508 · Cited by 9
Synthetic Antiviral Peptides: A New Way to Develop Targeted Antiviral Drugs
Parra, A. L. C., Bezerra, L. P., Shawar, D. E., Neto, N. A. S., Mesquita, F. P., da Silva, G. O., & Souza, P. F. N. (2022) · Future Virology · doi:10.2217/fvl-2021-0308 · Cited by 8
Malgave, A., Akbar, S., Joseph, A., Aishwarya, D., Peraman, R., & Malayandi, R. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114780 · Cited by 7
Emeh, P., Englund, M., Harun, S., Valencia, Z. S., Revell, J. D., Hugerth, A., Davies, N. M., & Bergström, C. A. S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114144 · Cited by 7
Milián-Guimerá, C., Tollemeto, M., Mortensen, J. S., Badillo‐Ramírez, I., Jernskæg, D. R., Mazarine, S. A. M., Essabar, A., Chang, T., Zhang, Z., Nielsen, H. M., et al. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126376 · Cited by 7
Park, S.-H., Ma, G., Park, S. J., Yang, S.-B., Seo, M., Lee, J.-H., Kweon, S., & Park, J. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123903 · Cited by 7
Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity
Chow, E. W.-K., & Chow, E. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02381-5 · Cited by 7
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100686 · Cited by 7
Andrzejczak, K., Kucharczyk, E., Korgiel, M., Drozdowska, J., Maj, J., & Ponikowska, M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050605 · Cited by 7
Xu, P., Nguyen, H. T., Huang, S., & Tran, H. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03785-0 · Cited by 7
Hironaka, J., Ushigome, E., Kondo, Y., Hashimoto, Y., Osaka, T., Majima, S., Nakanishi, N., Okada, H., Senmaru, T., Hamaguchi, M., et al. (2025) · Diabetes and Vascular Disease Research · doi:10.1177/14791641251318309 · Cited by 7
Emerging trends in permeation-enhancing technologies for oral peptide delivery
Tao, J., Yang, J., Zhao, M., Zhu, Q., Chen, Z., & Qi, J. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111170 · Cited by 7
Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus
Chatterjee, R., Galave, V. S. B., & Jindal, A. B. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01965-y · Cited by 7
Bardonnet, P.-L., Niu, Z., Pessi, J., Kazakou, M., Raptis, K., McCabe, R., Toftlev, A., Rebollo, R., Wang, Z., Fan, L., et al. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01978-7 · Cited by 7
Self-citationYagi, H., Tomono, T., Handa, Y., Saito, N., Ukawa, M., Miyata, K., Shigeno, K., & Sakuma, S. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00657 · Cited by 7
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D. L., Blasio, M. J. D., & Ritchie, R. H. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.03.007 · Cited by 7
Oral Delivery of Semaglutide and Tirzepatide Using Milk‐Derived Small Extracellular Vesicles
Zhang, Y., Han, J., Wu, W., & Dang, B. (2025) · Journal of Extracellular Biology · doi:10.1002/jex2.70099 · Cited by 7
Dening, T. J., Siahaan, T. J., & Hageman, M. J. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.12.018 · Cited by 7
Jiménez-Martí, E., Hurtado-Genovés, G., Aguilar-Ballester, M., Martínez‐Hervás, S., & Navarro, H. G. (2022) · Nutrients · doi:10.3390/nu14183775 · Cited by 7
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials
Brayden, D. J. (2022) · BioDrugs · doi:10.1007/s40259-022-00562-6 · Cited by 7
Huang, R., Yu, J., Zhang, B., Ran, W., Zhao, M., An, N. A., Ye, J., Li, J., Cao, E., Wang, Y., et al. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2025.139463 · Cited by 6
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 6
Dimba, N. R., Mzimela, N., & Khathi, A. (2024) · Biomedicines · doi:10.3390/biomedicines12061275 · Cited by 6
Compaction behavior of freeze-dried and spray-dried trypsin/lactose particulate systems
Zhang, C., Frenning, G., Radeke, C., Lind, J. U., Bjerregaard, S., Rantanen, J., & Yang, M. (2024) · Powder Technology · doi:10.1016/j.powtec.2024.120012 · Cited by 6
Self-citationNew, R. R. C., Bogus, M., Travers, G. N., Hahn, U., Vaiceliunaite, A., Burnet, M. W. M., Wang, J. H., & Wen, H. (2024) · Frontiers in Drug Delivery · doi:10.3389/fddev.2024.1456654 · Cited by 6
Novel approaches to pharmacological management of type 2 diabetes in Japan
Kaneko, S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1974401 · Cited by 6
Rajput, R., Sinha, B., Lodha, S., Deb, P., Das, S., Agarwal, S., Das, A. K., & Thomas, N. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0026 · Cited by 6
Clinical applications and future clinical trials of the drug delivery system
Çetin, K., Şarkaya, K., & Denizli, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95325-2.00020-1 · Cited by 6
Oral semaglutide: the innovation in type 2 diabetes management
Shestakova, M. V., Шамхалова, М. Ш., Galstyan, G. R., Ruyatkina, L. A., & Суплотова, Л. А. (2021) · Diabetes Mellitus · doi:10.14341/dm12790 · Cited by 6
Meier, J. J., Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.760153 · Cited by 6
Heteropolymer ferritin nanocages as delivery vehicles for oral delivery of GLP-1 peptides
Qian, Y., Chang, X., Sun, M., Chen, Y. B., Zang, J., Lv, C., Zhao, G., & Zhang, T. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2025.139092 · Cited by 5
Candido, R., Toffoli, B., Baccichetto, G., Marchese, F., Carpenè, S., Gaiotti, S., Fabris, B., & Bernardi, S. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02626-9 · Cited by 5
Naranjani, B., Hossain, S., Tjakra, M., Azhand, P., Bergström, C. A. S., Sinko, P. D., & Larsson, P. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2607779 · Cited by 5
Jeyavelkumaran, R., Harikrishnan, S., Saravanan, M. D., Keerthivasan, N., & Valliappan, S. (2026) · Peptide Science · doi:10.1002/pep2.70027 · Cited by 5
Inokuchi, T., Fukumoto, Y., Lee, G., 横溝由史, Tanaka, K., Chosa, M., Doi, M., Tamaki, N., Goto, S., Ichikawa, K., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14225 · Cited by 5
The Impact of Permeation Enhancers on Transcellular Permeation of Small Molecule Drugs
Bernaldez, M., Kang, C., Stamatis, S. D., Rose, J. P., & Sun, R. (2025) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c00953 · Cited by 5
Palazzi, S., Sentinelli, F., Zugaro, A., Morgante, S. N., Santarelli, L., Melanzi, S., Mutiis, A. D., Piersanti, D., Macerola, B., Iezzi, M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18060856 · Cited by 5
The road ahead for applications of mechanics in drug delivery
Sarmadi, M., Krishnan, S. R., Ramadi, K. B., & Langer, R. (2022) · Mechanics Research Communications · doi:10.1016/j.mechrescom.2022.103956 · Cited by 5
RoyChaudhuri, S., Majumder, A., Sanyal, D., Chakraborty, S., & Chuyan, S. (2023) · Cureus · doi:10.7759/cureus.37065 · Cited by 5
Itagaki, M., Kamei, N., & Takeda‐Morishita, M. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.05.013 · Cited by 5
Lund, P. M., Kristensen, K., Larsen, N. W., Knuhtsen, A., Hansen, M. B., Hjørringgaard, C. U., Eriksen, A. Z., Urquhart, A. J., Mortensen, K. I., Simonsen, J. B., et al. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2024.04.093 · Cited by 5
Efficacy and Safety of Oral Semaglutide in Managing Type 2 Diabetes in India: A Real-World Study
Ray, S., Ray, A., Goutam, S., & Mitra, A. (2024) · Clinical Diabetology · doi:10.5603/cd.102374 · Cited by 5
Cui, J., Klepser, D. G., & McAdam‐Marx, C. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.7.840 · Cited by 5
Future perspectives on peptide therapeutics
Ünsal, Ö., Liu, J., Sicinski, K. M., & Kumar, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820141-1.00003-0 · Cited by 5
Pawar, S. S., Rasal, P. B., Kulkarni, K. H., & Pawar, S. B. (2025) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v15i12.7452 · Cited by 4
pH Controlled Transient Cyclization of Peptides for Increased Stability towards Oral Delivery
Paprocki, M. P., Sørensen, K. K., & Jensen, K. J. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202403503 · Cited by 4
Oral absorption of semaglutide: pharmacokinetic modeling and molecular dynamics simulations
Agarwal, P., & Haworth, I. S. (2025) · In Silico Pharmacology · doi:10.1007/s40203-025-00393-7 · Cited by 4
Kanelli, M., Yu, A. C., Susilo, P. D., Petropulos, O., Kadasia, K., Sandoval, L., Hudson, M. A., Sim, D., Dial, C., Mena, M. B., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114338 · Cited by 4
Singh, R., & Daniell, H. (2026) · Plant Biotechnology Journal · doi:10.1111/pbi.70554 · Cited by 4
Akbar, S., Joseph, A., Malgave, A., Kumar, A., Bej, P., & Malayandi, R. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03424-4 · Cited by 4
Kim, D.-H., Hwang, S.-K., Yoon, J.-H., Na, D. H., Park, Y.-J., Chae, Y., Chang, J., & Kim, J.-E. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18060680 · Cited by 4
Granhall, C., Bækdal, T. A., Breitschaft, A., Søndergaard, F. L., Anderson, T. W., & Thomsen, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01106-x · Cited by 4
Self-citationRoyChaudhuri, S., Majumder, A., Mukherjee, P., Sanyal, D., Chakraborty, S., & Chuyan, S. (2023) · Cureus · doi:10.7759/cureus.40179 · Cited by 4
Sato, G. E., Uchino, H., & Hirose, T. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01631-5 · Cited by 4
Bioinspired orthogonal-shaped protein–biometal nanocrystals enable oral protein absorption
Durán‐Lobato, M., Tovar, S. A., Cuñarro, J., Ramos-Membrive, R., Peñuelas, I., Marigo, I., Benetti, F., Chenlo, M., Álvarez, C. V., Ildikó, V., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.016 · Cited by 4
Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone
Ferrara, F., Bazzani, D., Crivelli, B., Danieli, E., Gazzola, P., Guarnieri, G., Handschin, G., Lauria, C., Marchetti, C., Sbraga, E., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04319-0 · Cited by 4
Tomono, T., Yagi, H., Igi, R., Tabaru, A., Fujimoto, K., Enomoto, K., Ukawa, M., Miyata, K., Shigeno, K., & Sakuma, S. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123499 · Cited by 4
A Hundred Years of Insulin Innovation: When Science Meets Technology
Kjeldsen, T., & Kurtzhals, P. (2021) · Diabetes · doi:10.2337/db21-0430 · Cited by 4
Biopharmaceutics Tools for Rational Formulation Design
Zarmpi, P., McAllister, M. S., Butler, J., & Fotaki, N. (2021) · Wiley eBooks · doi:10.1002/9781119678366.ch8 · Cited by 4
Skak, N., Mertz, N., Piwon, N., Olsen, M. R., Caffarel–Salvador, E., Brayden, D. J., Østergaard, J., & Lindhardt, K. (2026) · Drug Delivery and Translational Research · doi:10.1007/s13346-026-02157-y · Cited by 3
Longer Fasting After Rybelsus Administration Contributes Higher Efficacy
Miki, K., Bando, H., Hayashi, K., Dohi, A., & Kamoto, A. (2022) · SunText Review of Medical & Clinical Research · doi:10.51737/2766-4813.2022.050 · Cited by 3
First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
Rajput, R., Ghosh, S., Banerjee, S., Bansal, B., Chawla, M. S., Ahluwalia, A. I., Lathia, T. B., & Das, A. K. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_217_22 · Cited by 4
Khamnueva, L. Y., & Андреева, Л. С. (2023) · Problems of Endocrinology · doi:10.14341/probl13245 · Cited by 3
Yagi, H., Tomono, T., Abe, K., Tsutsumi, Y., Makabe, M., Mitsuhashi, H., Kimura, T., Kobayashi, H., Miyata, K., Shigeno, K., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00184 · Cited by 3
Bapat, P., Luy, S. L., Panchabhai, N., & Taylor, L. S. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03870-y · Cited by 3
Metadata
- Authors
- Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., Pedersen, B. L., Skyggebjerg, R. B., Benie, A. J., Strauss, H. M., Wahlund, P.-O., Bjerregaard, S., Farkas, E., Fekete, C., Søndergaard, F. L., Borregaard, J., Hartoft-Nielsen, M.-L., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk A/S, 2760 Måløv, Denmark.
- HUN-REN Institute of Experimental Medicine (HU)
- Tufts Medical Center (US)
- Novo Nordisk A/S, 2860 Søborg, Denmark.
- Corresponding author
- Buckley, Stephen T.
- Bækdal, Tine A.
- Vegge, Andreas
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-11-14
- Volume
- 10
- Issue
- 467
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2901306081
- Cited by
- 553
- References
- 40
- Citations by year
- 2026: 84 · 2025: 89 · 2024: 74 · 2023: 53 · 2022: 73 · 2021: 77 · 2020: 69 · 2019: 32 · 2018: 1
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, GLP-1 receptor agonists, SNAC, gastric absorption, oral drug delivery, tablet formulation, tight junctions
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Oral, Adolescent, Adult, Aged, Animals, Cell Membrane, Dogs, Glucagon-Like Peptides, Epithelial Cells, Gastric Mucosa, Humans, Hydrogen-Ion Concentration, Intestinal Absorption, Male, Middle Aged, Stomach, Time Factors, Rats, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.